

【発表英文論文(2017~)】

1. Matsuzawa R, **Morise M***, Kinoshita F, **Tanaka I**, Koyama J, Kimura T, Kondoh Y, Tanaka T, Shima K, **Hase T**, Wakahara K, Ishii M, Hashimoto N. Non-invasive early prediction of immune checkpoint inhibitor efficacy in non-small-cell lung cancer patients using on-treatment serum CRP and NLR. *J Cancer Res Clin Oncol*. 2022 Aug 25. ***corresponding author**
2. Kobayashi T, Iwama S, Yamagami A, Yasuda Y, Okuji T, Ito M, Zhou X, Ando M, Onoue T, Miyata T, Sugiyama M, Hagiwara D, Suga H, Banno R, **Hase T**, **Morise M**, Ito T, Kikumori T, Inoue M, Ando Y, Masuda N, Kawashima H, Hashimoto N, Arima H. Elevated TSH Level, TgAb, and Prior Use of Ramucirumab or TKIs as Risk Factors for Thyroid Dysfunction in PD-L1 Blockade. *J Clin Endocrinol Metab*. 2022 Sep 28;107(10):e4115-e4123. PMID: 35918067
3. Gen S, **Tanaka I***, **Morise M**, Koyama J, Kodama Y, Matsui A, Miyazawa A, **Hase T**, Hibino Y, Yokoyama T, Kimura T, Yoshida N, Sato M & Hashimoto N. Clinical efficacy of osimertinib in EGFR-mutant non-small cell lung cancer with distant metastasis. *BMC Cancer*. 2022 Jun 14;22(1):654. PMID: 35698083 ***corresponding author**
4. Hata A, Shiraishi Y, Inui N, Okada M, **Morise M**, Akiyoshi K, Takeda M, Watanabe Y, Sugawara S, Shinagawa N, Kubota K, Saeki T, Tamura T. Exploratory Analysis Comparing Fosnetupitant Versus Fosaprepitant for Prevention of Highly Emetogenic Chemotherapy-Induced Nausea and Vomiting (CINV): A Randomized, Double-Blind, Phase 3 Study (CONSOLE) *Oncol Ther*. 2022 Jun;10(1):253-262. PMID: 35246827
5. **Tanaka I***, **Morise M**. Current Immunotherapeutic Strategies Targeting the PD-1/PD-L1 Axis in Non-Small Cell Lung Cancer with Oncogenic Driver Mutations. *Int. J. Mol. Sci*. 2022, 23(1), 245; PMID: 35008669 ***corresponding author**
6. Fahrman JF, **Tanaka I**, Irajizad E, Mao X, Dennison JB, Murage E, Casabar J, Mayo J, Peng Q, Celiktas M, Vykoukal JV, Park S, Taguchi A, Delgado O, Tripathi SC, Katayama H, Soto LMS, Rodriguez-Canales J, Behrens C, Wistuba I, Hanash S, Ostrin EJ. Mutational Activation of the NRF2 Pathway Upregulates Kynureninase Resulting in Tumor Immunosuppression and Poor Outcome in Lung Adenocarcinoma *Cancers (Basel)*. 2022 May21;14(10):2543. PMID: 35626147
7. Iwama S, Kobayashi T, Yasuda Y, Okuji T, Ito M, Ando M, Zhou X, Yamagami A, Onoue T, Kawaguchi Y, Miyata T, Sugiyama M, Takagi H, Hagiwara D, Suga H, Banno R, **Hase T**, **Morise M**, Wakahara K, Yokota K, Kato M, Nishio N, Tanaka C, Miyata K, Ogura A, Ito T, Sawada T, Shimokata T, Niimi K, Ohka F, Ishigami M, Gotoh M, Hashimoto N, Saito R, Kiyoi H, Kajiyama H, Ando Y, Hibi H, Sone M, Akiyama M, Koderia Y, Arima H. Increased Risk of Thyroid Dysfunction by PD-1 and CTLA-4 Blockade in Patients Without Thyroid Autoantibodies at Baseline *J Clin Endocrinol Metab*. 2022 Mar 24;107(4):e1620-e1630. PMID: 34791304
8. Muraki N, Yamada M, Doki H, Nakai R, Komeda K, Goto D, Kawabe N, Matsuoka K, Matsushima M, Kawabe T, **Tanaka I**, **Morise M**, Shay JW, Minna JD, Sato M. Resistance to mutant KRAS V12-induced senescence in an hTERT/Cdk4-immortalized normal human bronchial epithelial cell line *Exp Cell Res*. 2022;414:113053. PMID: 35149086
9. Matsuzawa R, **Morise M***, **Tanaka I**, Hayai S, Tamiya Y, Koyama J, **Hase T**, Wakahara K, Kim D, Shimoyama Y, Hashimoto N. Amelanotic Malignant Melanoma with a BRAF V600E Mutation Mimicking Primary Lung Cancer *Intern Med*. 2022;61:703-708. PMID: 34433708 ***corresponding author**
10. Oi H, Matsuda T, Kimura T, **Morise M**, Yamano Y, Yokoyama T, Kataoka K, Kondoh Y. Weekly nanoparticle albumin-bound paclitaxel and paclitaxel for relapsed small cell lung cancer: A retrospective observational study *Medicine (Baltimore)*. 2022 Feb 11;101(6):e28863. PMID: 35147134
11. Iwama E, Zenke Y, Sugawara S, Daga H, **Morise M**, Yanagitani N, Sakamoto T, Murakami H, Kishimoto J, Matsumoto S, Nakanishi Y, Goto K, Okamoto I. Trastuzumab emtansine for patients with non-small cell lung cancer positive for human epidermal growth factor receptor 2 exon-20 insertion mutations *Eur J Cancer*. 2022 Feb;162:99-106. PMID: 34959152
12. Hata A, Okamoto I, Inui N, Okada M, **Morise M**, Akiyoshi K, Takeda M, Watanabe Y,

- Sugawara S, Shinagawa N, Kubota K, Saeki T, Tamura T. Randomized, Double-Blind, Phase III Study of Fosnetupitant Versus Fosaprepitant for Prevention of Highly Emetogenic Chemotherapy-Induced Nausea and Vomiting: CONSOLE *J Clin Oncol*. 2022 Jan 10;40(2):180-188. PMID: 34793245
13. Yasuda H, Ichihara E, Sakakibara-Konishi J, Zenke Y, Takeuchi S, **Morise M**, Hotta K, Sato M, Matsumoto S, Tanimoto A, Matsuzawa R, Kiura K, Takashima Y, Yano S, Koyama J, Fukushima T, Hamamoto J, Terai H, Ikemura S, Takemura R, Goto K, Soejima K. A phase I/II study of osimertinib in EGFR exon 20 insertion mutation-positive non-small cell lung cancer *Lung Cancer*. 2021 Dec;162:140-146.
 14. Ozone S, Ichikawa K, **Morise M***, Matsui A, Kinoshita F, Matsuzawa R, Koyama J, **Tanaka J**, Hashimoto N: Is area under the curve the best parameter for carboplatin induced emetic risk stratification? *Nagoya J Med Sci*. 2021 Nov;83(4):773-785. PMID: 34916721 ***corresponding author**
 15. Jassem J, de Marinis F, Giaccone G, Vergnenegre A, Barrios CH, **Morise M**, Felip E, Oprean C, Kim YC, Andric Z, Mocchi S, Enquist I, Komatsubara K, McClelland M, Kuriki H, Villalobos M, Phan S, Spigel DR, Herbst RS. Updated Overall Survival Analysis From IMpower110: Atezolizumab Versus Platinum-Based Chemotherapy in Treatment-Naive Programmed Death-Ligand 1-Selected NSCLC *J Thorac Oncol*. 2021 Nov;16(11):1872-1882. PMID: 34265434
 16. **Tanaka I**, Daye D, Tai MC, Mori H, Solis LM, Tripathi SC, Fahrman JF, Unver N, Parhy G, Jain R, Parra ER, Murakami Y, Aguilar-Bonavides C, Mino B, Celiktas M, Dhillon D, Casabar JP, Nakatochi M, Stingo F, Baladandayuthapani V, Wang H, Katayama H, Dennison JB, Lorenzi PL, Do KA, Fujimoto J, Behrens C, Ostrin EJ, Rodriguez-Canales J, **Hase T**, Fukui T, Kajino T, Kato S, Yatabe Y, Hosoda W, Kawaguchi K, Yokoi K, Chen-Yoshikawa TF, Hasegawa Y, Gazdar AF, Wistuba II, Hanash S, Taguchi A: SRGN-Triggered Aggressive and Immunosuppressive Phenotype in a Subset of TTF-1-Negative Lung Adenocarcinomas. *J Natl Cancer Inst*. 2021 Sep 15. PMID: 34524427
 17. Kodama Y, **Tanaka I***, Sato T, Hori K, Gen S, **Morise M**, Matsubara D, Sato M, Sekido Y, Hashimoto N.: Oxytocin receptor is a promising therapeutic target of malignant mesothelioma. *Cancer Sci*. 2021 Sep;112(9):3520-3532. ***corresponding author**
 18. **Tanaka I***, Furukawa T, Morise M.: The current issues and future perspective of artificial intelligence for developing new treatment strategy in non-small cell lung cancer: harmonization of molecular cancer biology and artificial intelligence. *Cancer Cell Int*. 2021 Aug 26;21(1):454. PMID: 34446006 ***corresponding author**
 19. Ishi A, **Tanaka I***, Iwama S, Sakakibara T, Mastui T, Kobayashi T, **Hase T**, **Morise M**, Sato M, Arima H, Hashimoto N. (*corresponding author): Efficacies of programmed cell death 1 ligand 1 blockade in non-small cell lung cancer patients with acquired resistance to prior programmed cell death 1 inhibitor and development of diabetic ketoacidosis caused by two different etiologies: a retrospective case series. *Endocr J*. 2021 May 28;68(5):613-620. PMID: 33790087 ***corresponding author**
 20. Sakai H, **Morise M**, Kato T, Matsumoto S, Sakamoto T, Kumagai T, Tokito T, Atagi S, Kozuki T, Tanaka H, Chikamori K, Shinagawa N, Takeoka H, Bruns R, Straub J, Schumacher KM, Paik PK. Tepotinib in patients with NSCLC harbouring MET exon 14 skipping: Japanese subset analysis from the Phase II VISION study *Jpn J Clin Oncol*. 2021 Aug 1;51(8):1261-1268.
 21. Nakagawa K, Kijima T, Okada M, **Morise M**, Kato M, Hirano K, Fujimoto N, Takenoyama M, Yokouchi H, Ohe Y, Hida T, Aoe K, Kishimoto T, Hirokawa M, Matsuki H, Kaneko Y, Yamada T, Morimoto C, Takeda M. Phase 2 Study of YS110, a Recombinant Humanized Anti-CD26 Monoclonal Antibody, in Japanese Patients With Advanced Malignant Pleural Mesothelioma *JTO Clin Res Rep*. 2021 Apr 29;2(6):100178.
 22. Bevacizumab plus cisplatin/pemetrexed then bevacizumab alone for unresectable malignant pleural mesothelioma: A Japanese safety study Nakano T, Kuribayashi K, Kondo M, **Morise M**, Tada Y, Hirano K, Hayashi M, Tanaka M, Hirabayashi M. *Asia Pac J Clin Oncol*. 2021 Jun;17(3):264-272.
 23. Ninomiya K, Teraoka S, Zenke Y, Kenmotsu H, Nakamura Y, Okuma Y, Tamiya A, Nosaki K,

- Morise M**, Aokage K, Oya Y, Kozuki T, Sakamoto T, Tanaka K, Tanaka H, Tanizaki J, Miura S, Mizutani H, Miyauchi E, Yamaguchi O, Ebi N, Goto Y, Sasaki T, Daga H, Morita S, Yamanaka T, Amano S, Hasegawa K, Imamura CK, Suzuki K, Nakajima K, Nishimoto H, Oizumi S, Hida T, Hotta K, Takiguchi Y. Japanese Lung Cancer Society Guidelines for Stage IV NSCLC With EGFR Mutations *JTO Clin Res Rep*. 2020 Oct 12;2(1):100107.
24. Takeuchi S, Yanagitani N, Seto T, Hattori Y, Ohashi K, **Morise M**, Matsumoto S, Yoh K, Goto K, Nishio M, Takahara S, Kawakami T, Imai Y, Yoshimura K, Tanimoto A, Nishiyama A, Murayama T, Yano S. Phase 1/2 study of alectinib in RET-rearranged previously-treated non-small cell lung cancer (ALL-RET) *Transl Lung Cancer Res*. 2021 Jan;10(1):314-325.
 25. Herbst RS, Giaccone G, de Marinis F, Reinmuth N, Vergnenegre A, Barrios CH, **Morise M**, Felip E, Andric Z, Geater S, Özgüroğlu M, Zou W, Sandler A, Enquist I, Komatsubara K, Deng Y, Kuriki H, Wen X, McClelland M, Mocchi S, Jassem J, Spigel DR. Atezolizumab for First-Line Treatment of PD-L1-Selected Patients with NSCLC *N Engl J Med*. 2020 Oct 1;383(14):1328-1339.
 26. Seto T, Hayashi H, Satouchi M, Goto Y, Niho S, Nogami N, Hida T, Takahashi T, Sakakibara-Konishi J, **Morise M**, Nagasawa T, Suzuki M, Ohkura M, Fukuhara K, Thurm H, Peltz G, Nishio M. Lorlatinib in previously treated anaplastic lymphoma kinase-rearranged non-small cell lung cancer: Japanese subgroup analysis of a global study *Cancer Sci*. 2020 Oct;111(10):3726-3738.
 27. **Tanaka I***, **Morise M**, Miyazawa A, Kodama Y, Tamiya Y, Soei Gen, Matsui A, Hase T, Hashimoto N, Sato M, Hasegawa Y. Potential Benefits of Bevacizumab Combined with Platinum-Based Chemotherapy in Advanced Non-Small-Cell Lung Cancer Patients With EGFR Mutation. *Clin Lung Cancer* 2020 May;21(3):273-280.e4. PMID: 32088115 *corresponding author
 28. Sakamoto K, Fukihara J, **Morise M**, Hashimoto N. Clinical burden of immune checkpoint inhibitor-induced pneumonitis *Respir Investig*. 2020 Sep;58(5):305-319.
 29. Matsui A, **Morise M***, Tanaka I, Ozone S, Matsuzawa R, Koyama J, Hase T, Hashimoto N, Sato M, Hasegawa Y. Primary Prophylaxis Indication for Docetaxel Induced Febrile Neutropenia in Elderly Patients with Non-Small Cell Lung Cancer *Cancer Invest*. 2020 Aug;38(7):424-430. PMID: 32643445 *corresponding author
 30. Kobayashi T, Iwama S, Yasuda Y, Okada N, Okuji T, Ito M, Onoue T, Goto M, Sugiyama M, Tsunekawa T, Takagi H, Hagiwara D, Ito Y, Suga H, Banno R, Yokota K, **Hase T**, **Morise M**, Hashimoto N, Ando M, Fujimoto Y, Hibi H, Sone M, Ando Y, Akiyama M, Hasegawa Y, Arima H. Pituitary dysfunction induced by immune checkpoint inhibitors is associated with better overall survival in both malignant melanoma and non-small cell lung carcinoma: a prospective study *J Immunother Cancer*. 2020 Jul;8(2):e000779. PMID: 32606047
 31. Fahrman JF, Mao X, Irajizad E, Katayama H, Capello M, **Tanaka I**, Kato T, Wistuba II, Maitra A, Ostrin EJ, Hanash SM, Vykoukal J: Plasma-Derived Extracellular Vesicles Convey Protein Signatures That Reflect Pathophysiology in Lung and Pancreatic Adenocarcinomas. *Cancers (Basel)*. 2020 May 2;12(5):E1147. PMID: 32370304
 32. Goto D, Komeda K, Uwatoko N, Nakashima M, Koike M, Kawai K, Kodama Y, Miyazawa A, **Tanaka I**, **Hase T**, **Morise M**, Hasegawa Y, Kawabe T, Sato M: *Cancer Invest*. 2020 Apr;38(4):240-249. PMID: 32212938
 33. Shimokawa M, Nosaki K, Seto T, Ohashi K, **Morise M**, Horinouchi H, Sakakibara J, Murakami H, Yano S, Satouchi M, Matsumoto S, Goto K, Yoh K. Phase II, open-label, multicenter trial of crizotinib in Japanese patients with advanced non-small cell lung cancer harboring a MET gene alteration: Co-MET study *Trials*. 2020 Mar 30;21(1):298. PMID: 32228679
 34. Okada N, Iwama S, Okuji T, Kobayashi T, Yasuda Y, Wada E, Onoue T, Goto M, Sugiyama M, Tsunekawa T, Takagi H, Hagiwara D, Ito Y, Suga H, Banno R, **Hase T**, **Morise M**, Kanda M, Yokota K, Hashimoto N, Ando M, Fujimoto Y, Nagino M, Kodera Y, Fujishiro M, Hibi H, Sone M, Kiyoi H, Gotoh M, Ando Y, Akiyama M, Hasegawa Y, Arima H. Anti-thyroid antibodies and thyroid echo pattern at baseline as risk factors for thyroid dysfunction induced by anti-programmed cell death-1 antibodies: a prospective study *Br J Cancer*. 2020

- Mar;122(6):771-777. PMID: 32009131
35. Nakagawa K, Hida T, Nokihara H, **Morise M**, Azuma K, Kim YH, Seto T, Takiguchi Y, Nishio M, Yoshioka H, Kumagai T, Hotta K, Watanabe S, Goto K, Satouchi M, Kozuki T, Koyama R, Mitsudomi T, Yamamoto N, Asakawa T, Hayashi M, Hasegawa W, Tamura T. Final progression-free survival results from the J-ALEX study of alectinib versus crizotinib in ALK-positive non-small-cell lung cancer *Lung Cancer*. 2020 Jan;139:195-199. PMID: 31812890
 36. Shimizu T, Okachi S, Imai N, **Hase T**, **Morise M**, Hashimoto N, Sato M, Hasegawa Y. Risk factors for pulmonary infection after diagnostic bronchoscopy in patients with lung cancer *Nagoya J Med Sci*. 2020 Feb;82(1):69-77. PMID: 32273634
 37. **Tanaka I***, **Morise M**, Kodama Y, Matsui A, Ozawa N, Ozone S, Goto D, Miyazawa A, **Hase T**, Hashimoto N, Sato M, Hasegawa Y.: Potential for afatinib as an optimal treatment for advanced non-small cell lung carcinoma in patients with uncommon EGFR mutations. *Lung Cancer*, 2019 Jan;127:169-171 ***corresponding author**
 38. Sugawara S, Inui N, Kanehara M, **Morise M**, Yoshimori K, Kumagai T, Fukui T, Minato K, Iwashima A, Takeda Y, Kubota K, Saeki T, Tamura T. Multicenter, placebo-controlled, double-blind, randomized study of fosnetupitant in combination with palonosetron for the prevention of chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy *Cancer*. 2019 Nov 15;125(22):4076-4083. PMID: 31381152
 39. Fukihara J, Sakamoto K, Koyama J, Ito T, Iwano S, **Morise M**, Ogawa M, Kondoh Y, Kimura T, Hashimoto N, Hasegawa Y. Prognostic Impact and Risk Factors of Immune-Related Pneumonitis in Patients With Non-Small-Cell Lung Cancer Who Received Programmed Death 1 Inhibitors *Clin Lung Cancer*. 2019 Nov;20(6):442-450.e4. PMID: 31446020
 40. Akamatsu H, Ninomiya K, Kenmotsu H, **Morise M**, Daga H, Goto Y, Kozuki T, Miura S, Sasaki T, Tamiya A, Teraoka S, Tsubata Y, Yoshioka H, Hattori Y, Imamura CK, Katsuya Y, Matsui R, Minegishi Y, Mizugaki H, Nosaki K, Okuma Y, Sakamoto S, Sone T, Tanaka K, Umemura S, Yamanaka T, Amano S, Hasegawa K, Morita S, Nakajima K, Maemondo M, Seto T, Yamamoto N. The Japanese Lung Cancer Society Guideline for non-small cell lung cancer, stage IV *Int J Clin Oncol*. 2019 Jul;24(7):731-770. PMID: 31049758
 41. Ito T, Nakamura A, **Tanaka I**, Tsuboi Y, Morikawa T, Nakajima J, Takai D, Fukayama M, Sekido Y, Niki T, Matsubara D, Murakami Y: CADM1 associates with Hippo pathway core kinases; membranous co-expression of CADM1 and LATS2 in lung tumors predicts good prognosis. *Cancer Sci*. 2019 Jul;110(7):2284-2295. PMID: 31069869
 42. **Tanaka I**, Sato M, Kato T, Goto D, Kakumu T, Miyazawa A, Yogo N, **Hase T**, **Morise M**, Sekido Y, Girard L, Minna JD, Byers LA, Heymach JV, Coombes KR, Kondo M, Hasegawa Y: eIF2 β , a subunit of translation-initiation factor EIF2, is a potential therapeutic target for non-small cell lung cancer. *Cancer Sci*, 2018 Jun;109(6):1843-1852. PMID: 29624814
 43. Sato M, Matsui A, Shimoyama Y, Omote N, **Morise M**, **Hase T**, **Tanaka I**, Suzuki K, Hasegawa Y: An EGFR-mutated Lung Adenocarcinoma Undergoing Squamous Cell Carcinoma Transformation Exhibited a Durable Response to Afatinib. *Intern Med*, 2018 Dec 1;57(23):3429-3432. PMID: 30101911
 44. Shintani Y, Hasegawa S, Takuwa T, Aoe K, Kato K, Fujimoto N, Hida Y, **Morise M**, Moriya Y, Morohoshi T, Okumura M, Yoshino I. Prospective registry database of patients with malignant mesothelioma: directions for a future Japanese registry-based lung cancer study *J Thorac Dis*. 2018 PMID: 29707353
 45. Okachi S, Imaizumi K, Imai N, Shimizu T, **Hase T**, **Morise M**, Hashimoto N, Sato M, Hasegawa Y. Safety and efficacy of diagnostic flexible bronchoscopy in very old patients with lung cancer *Eur Geriatr Med*. 2018 Apr;9(2):255-262. PMID: 34654258
 46. Kobayashi T, Iwama S, Yasuda Y, Okada N, Tsunekawa T, Onoue T, Takagi H, Hagiwara D, Ito Y, Morishita Y, Goto M, Suga H, Banno R, Yokota K, **Hase T**, **Morise M**, Hashimoto N, Ando M, Kiyoi H, Gotoh M, Ando Y, Akiyama M, Hasegawa Y, Arima H. Patients With Antithyroid Antibodies Are Prone To Develop Destructive Thyroiditis by Nivolumab: A Prospective Study *J Endocr Soc*. 2018 Feb 6;2(3):241-251. doi: 10.1210/js.2017-00432. eCollection 2018 Mar 1. PMID: 29600292

47. **Tanaka I***, Kawada K, **Morise M**, **Hase T**, Hayashi H, Sokai A, Fukatsu A, Kondo M, Nomura F, Hasegawa Y: A phase II trial of Ifosfamide combination with recommended supportive therapy for recurrent SCLC in second-line and heavily treated setting *Cancer Chemother Pharmacol*, 2018 Feb;81(2):339-345. PMID: 29234921 *corresponding author
48. Miyazawa A, Ito S, Asano S, **Tanaka I**, Sato M, Kondo M, Hasegawa Y: Regulation of PD-L1 expression by matrix stiffness in lung cancer cells. *Biochem Biophys Res Commun*, 2018 Jan 15;495(3):2344-2349. PMID: 29274784
49. Omote N, Hashimoto N, **Morise M**, Sakamoto K, Miyazaki S, Ando A, Nakahara Y, Hasegawa Y. Impact of mild to moderate COPD on feasibility and prognosis in non-small cell lung cancer patients who received chemotherapy *Int J Chron Obstruct Pulmon Dis*. 2017 Dec 11;12:3541-3547. doi: 10.2147/COPD.S149456. eCollection 2017. PMID: 29270008
50. Çeliktas M*, **Tanaka I***(同等貢献筆頭著者), Chandra Tripathi S, Fahrman JF, Aguilar-Bonavides C, Villalobos P, Delgado O, Dhillon D, Dennison JB, Ostrin EJ, Wang H, Behrens C, Do KA, Gazdar AF, Hanash SM, Taguchi A: Role of CPS1 in Cell Growth, Metabolism, and Prognosis in LKB1-Inactivated Lung Adenocarcinoma. *J Natl Cancer Inst*, 2017;109(3): 1-9. PMID: 28376202
51. Daye D, **Tanaka I**, Jain R, Tai MC, Taguchi A: Predictive and Prognostic Molecular Biomarkers for Response to Neoadjuvant Chemoradiation in Rectal Cancer. *Int J Mol Sci*, 2017;18(3): pii: E573. PMID: 28272347
52. Jody Vykoukal, Nan Sun, Clemente Aguilar-Bonavides, Katayama H, **Tanaka I**, Johannes F. Fahrman, Michela Capello, Junya Fujimoto, Mitzi Aguilar, Ignacio I. Wistuba, Taguchi A, Edwin J. Ostrin and Samir M. Hanash: Plasma-derived extracellular vesicle proteins as a source of biomarkers for lung adenocarcinoma. *Oncotarget*. 2017; 8:95466-95480. PMID: 29221141

【発表和文論文・書籍】

1. **森瀬昌宏**. NRG1融合遺伝子陽性肺癌 呼吸器症候群(第3版)V(分担執筆)
日本臨床社, 2021
2. **森瀬昌宏**. 日本肺癌学会 肺癌診療ガイドライン2020年版(分担執筆)金原出版, 2020
3. **森瀬昌宏**, **田中一大** 日本呼吸器学会 大気・室内環境関連疾患予防と対策の手引き 2019
(分担執筆)メディカルレビュー社, 2019
4. **森瀬昌宏**. 日本肺癌学会 肺癌診療ガイドライン2018年版(分担執筆)金原出版, 2018
5. **森瀬昌宏**. 日本肺癌学会 肺癌診療ガイドライン IV期非小細胞肺癌薬物療法(分担執筆)
金原出版, 2018
6. **田中一大**. 肺がん・悪性中皮腫のメカノバイオロジーとYAP/TAZの役割「呼吸臨床」創刊 1号
1巻 論文番号:e00020 DOI: 10.24557, 2017

【公的研究費(2017~)】

森瀬昌宏

1. **H31~R4年度 科学研究費補助金:基盤研究(C)代表**
「呼吸器悪性腫瘍における血管新生阻害治療の低侵襲な効果予測法確立をめざす研究」
2. **H27~R29年度 科学研究費補助金:基盤研究(C)代表**
「高齢者悪性胸膜中皮腫に対する治療選択の最適化をめざした基盤構築」
3. **R1~R3年度 先端医療開発経費 代表**
「プラチナ製剤と免疫チェックポイント阻害剤を含む一次治療後に進行した非小細胞肺癌を対象とするドセタキセル・ラムシルマブ併用の第II相試験」
4. **Lilly Investigator-Initiated Research (IIR) Program 代表**
「Phase II study of docetaxel plus ramucirumab after treatment of platinum based chemotherapy combined with immune check point inhibitors in patients with non-small cell lung cancer (SCORPION Study)」
5. **Boehringer Ingelheim, Investigator-Initiated Research (IIR) Program代表**
「Basket study of afatinib maleate (BIBW2992) in patients with solid tumors harboring NRG1 fusion for evaluating efficacy and safety (Alsace Trial)」
6. **R2~R4年度 科学研究費補助金:基盤研究(B)分担**

- 「悪性中皮腫におけるオキシトシン受容体を標的とした新規治療法の開発」
7. **H15～H17年度 科学研究費補助金:基盤研究(C)分担**
「高齢者進行肺癌患者における、VES-13ならびにMMSEの有用性に関する検討」
 8. **R1～R4年度 AMED 革新的がん医療実用化研究事業 分担**
「進行肺癌の血漿遊離DNAを利用したマルチ遺伝子解析法に基づく個別化医療の確立を目指す研究」
 9. **R4年度 AMED 革新的がん医療実用化研究事業 分担**
「RET肺がんに対するアレクチニブの医師主導治験と耐性克服を目指したリバースTR」
 10. **H32～R4年度 AMED 革新的がん医療実用化研究事業 分担**
「ROS1融合遺伝子陽性の進行固形癌に対する治療開発をめざした研究」
 11. **H32～R3年度 AMED 革新的がん医療実用化研究事業 分担**
「次世代シーケンサーによる網羅的がん関連遺伝子パネル解析を用いたHER2遺伝子変異陽性の進行非小細胞肺癌に対する治療開発を目指した研究」
 12. **H29～R1年度 AMED 革新的がん医療実用化研究事業 分担**
「遺伝子スクリーニング基盤(LC-SCRUM-Japan)を利用した、MET遺伝子異常陽性の進行非小細胞肺癌に対する治療開発を目指した研究」
 13. **H29～R3年度 AMED 革新的がん医療実用化研究事業 分担**
「希少遺伝子変異を有する小細胞肺癌に対する新規治療法の確立に関する研究」
- 田中一大
1. **R4年度AMED 橋渡し研究プログラム/創薬基盤推進研究事業 代表**
「オキシトシン受容体を標的とした悪性中皮腫における新規個別化治療の確立」
 2. **R3～R4年度 AMED次世代がん医療創生研究事業 代表**
「分泌タンパク質SMOC1を標的としたLKB1不活化肺癌における新規治療戦略の構築」
 3. **R3年度 先端研究支援経費 代表**
「LKB1不活化肺癌に対する新規治療戦略の構築」
 4. **R3年度 公益財団法人 堀科学芸術振興財団 研究助成 代表**
「LKB1不活化肺癌におけるピリミジン塩基合成経路を標的とした新規治療法の確立」
 5. **R4～R6年度 APSR Assembly Fund Projects 分担**
Developing a novel synthetic lethal treatment with long non-coding RNA (lncRNA) for KRAS-mutated lung cancer
 6. **R3～R5年度 科学研究費補助金:基盤研究(B)分担**
「ドライバー癌遺伝子誘導性の細胞老化を作用機序とする変異KRAS肺癌の創薬研究」
 7. **R2～R4年度 科学研究費補助金:基盤研究(B)代表**
「悪性中皮腫におけるオキシトシン受容体を標的とした新規治療法の開発」
 8. **R2年度 橋渡し研究戦略的推進プログラム シーズA 代表**
「オキシトシン受容体を標的とした悪性中皮腫における新規個別化治療の確立」
 9. **R1～R2年度 公益財団法人 日東学術振興財団 研究助成 代表**
「悪性中皮腫に対する新規治療法の開発に向けたPatient-derived xenograft (PDX) マウスモデルの作成」
 10. **H31年度 公益財団法人愛知県がん研究振興会 がんその他の悪性新生物研究助成金 代表**
「LKB1が不活化した肺癌におけるSMOC1を標的とした新規治療戦略の構築」
 11. **H30～31年度 科学研究費補助金:若手研究 代表**
「LKB1が不活化した肺癌における腫瘍進展のメカニズムの解明」
 12. **R2年度 American Lung Association Lung Cancer Discovery Award 分担**
「The role of KYNU upregulation in lung adenocarcinoma」
 13. **H30～R2年度 科学研究費補助金:基盤研究(B)分担**
「ドライバー癌遺伝子により誘導される細胞老化(OIS)を利用した肺癌治療の開発」
 14. **H30～R2年度 科学研究費補助金:挑戦的研究(萌芽) 分担**
「部分的上皮間葉細胞転換(ハイブリッドEMT)の安定化因子を標的とする肺癌治療」